Q-omics provides the consensus-scored MIR8073 profile across patient tissues and cancer cell-line models. MIR8073 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR8073 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, MIR8073 RNA expression shows 9,162 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight MESO, BRCA, and COAD as cancer lineages where MIR8073 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR8073 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR8073 survival associations across molecular data types. MIR8073 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR8073 RNA expression–survival associations across cancer types. High MIR8073 expression shows unfavorable associations in MESO, UCS, BLCA, ACC, LGG and HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR8073 RNA expression.
This table summarizes MIR8073 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR8073. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR8073 shows lower tumor expression in BRCA, THCA and UCEC. The BRCA box plot shows higher MIR8073 RNA expression in normal versus tumor tissue (log2 FC = −0.286, t-test p = .017).
This table shows molecular features associated with MIR8073 in patient tissues and cancer cell lines. In patient samples, MIR8073 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
